CLINICAL AND BIOCHEMICAL ASPECTS OF THE USE OF MAGNESIUM IN OBSTETRICS, GYNECOLOGY AND PERINATOLOGY
Abstract
Significant biochemical role of magnesium in the body is well-known, as well as good proven clinical efficacy of magnesium in obstetrics and gynecology. Magnesium preparations, in particular magnesium sulfate, are recommended as the treatment of choice for premature birth, pre-eclampsia and eclampsia. There is evidence and its neuroprotective effects on the fetus. Restricts the use of magnesium sulfate possibility of overdose with serious side effects. Reduce the risk of overdose can be minimized using standard protocols, independent double-check, monitoring the patient’s
condition. Magnesium sulfate therapy, as a means of emergency, cannot compensate for a deficiency of magnesium, which is associated with the development of obstetric pathologies such as threatened miscarriage, premature birth, placental insufficiency, preeclampsia, thrombophilia, premenstrual syndrome (PMS), the appointment of combined oral contraceptives (COCs) and hormone replacement therapy (HRT), climacteric syndrome. Justified use of organic salts of magnesium orally – along with better bioavailability they do not lead to serious side effects in overdose. Using organic
magnesium salts to control magnesium deficiency and related symptoms is also shown at the ICP, and the appointment of COCs HRT during menopause. The use of magnesium citrate is the most preferred because citrate anion causes high bioavailability of magnesium, it is also required in the Krebs cycle and recycled into carbon dioxide and water. This
makes it an ideal transporter of magnesium into cells.
condition. Magnesium sulfate therapy, as a means of emergency, cannot compensate for a deficiency of magnesium, which is associated with the development of obstetric pathologies such as threatened miscarriage, premature birth, placental insufficiency, preeclampsia, thrombophilia, premenstrual syndrome (PMS), the appointment of combined oral contraceptives (COCs) and hormone replacement therapy (HRT), climacteric syndrome. Justified use of organic salts of magnesium orally – along with better bioavailability they do not lead to serious side effects in overdose. Using organic
magnesium salts to control magnesium deficiency and related symptoms is also shown at the ICP, and the appointment of COCs HRT during menopause. The use of magnesium citrate is the most preferred because citrate anion causes high bioavailability of magnesium, it is also required in the Krebs cycle and recycled into carbon dioxide and water. This
makes it an ideal transporter of magnesium into cells.
Keywords
About the Authors
K. Dadak
Department of Gynecology and Obstetrics, Department of basic and advanced international postgraduate education, Medical University of Vienna (Austria)
Austria
Austria
A. D. Makatsariya
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
D. V. Blinov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
U. V. Zimovina
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
References
1. Blinov D.V. Epilepsiya i paroksizmal’nye sostoyaniya. 2011; 2: 28-33.
2. Blinov D.V. Akusherstvo, ginekologiya i reproduktsiya. 2011 (2): 5-12.
3. Gromova O.A., Limanova O.A., Torshin I.Yu. Akusherstvo, ginekologiya i reproduktsiya. 2013; 7 (3): 35-50.
4. Gromova O.A. Pediatricheskaya Farmakologiya. 2014; 1: 20-30.
5. Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh., Dzhobava E.M. Voprosy ginekologii akusherstva i perinatologii. 2012; 11: 25-34.
6. Role of magnesium deficiency in obstetrics and gynecology (position paper). The authors. [Rol’ defitsita magniya v akusherstve i ginekologii (pozitsiya ekspertov). Kollektiv avtorov]. Akusherstvo i Ginekologiya. 2014; 1.
7. Reference data. Ministry of Health; SCOGP [Spravochnye dannye Minzdravsotsrazvitiya RF, NTs AGiP imeni akademika Kulakova]. Moscow. 2008.
8. Strizhakov A.N. i dr. Voprosy ginekologii, akusherstva i perinatologii. 2009; 8 (3): 5-18.
9. Amighi J., Sabeti S. et al. Low Serum Magnesium Predicts Neurological Events in Patients with Advanced Atherosclerosis. Stroke. 2004: 35:22
10. Almonte R.A., Heath D.L., Whitehall J., Russell M.J., Patole S., Vink R. Gestational magnesium deficiency is deleterious to fetal outcome. Biol. Neonate. 1999 Jul; 76 (1): 26-32.
11. Crowther C.A., Hiller J.E., Doyle L.W. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews. 2002; 4. Art. No.: CD001060.
12. Crowther C.A., Hiller J.E., Doyle L.W., Haslam R.R.; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003; 290 (20): 2669-2676.
13. Doyle L.W., Crowther C.A., Middleton P., Marret S., Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews. 2009; 1. Art. No.: CD004661.
14. Duley L., Gülmezoglu A.M., Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev. 2010; 9: CD002960.
15. Ebel H., Gunther T. Magnesium metabolism: a review. J. Clin. Chem. & Clin. Biochem. 1998; 18: 257-70.
16. Feldeisen S.E., Tucker K.L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab. 2007; 32 (1): 46-60.
17. Higdon J. An Evidence-Based Approach to Vitamins and minerals. New York-Stuttgart, 2005.
18. Jackson R.A., Gibson K.A., Wu Y.W. et al. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet. And Gynecol. 2004; 104 (2): 551-563.
19. Leitich H., Brumbauer M., Kaider A. et al. Cervical length and dilation of the internal as detected by vaginal ultrasonography as markers for preterm delivery: a systematic review. Am. J. Obstet. Gynecol. 1999; 181: 1465-1472.
20. Medication Errors in Labor and Delivery: Reducing Maternal and Fetal Harm. Pa Patient Saf. Advis. 2009; 16 (6; Suppl. 1): 1-6.
21. Mercer B.M., Goldenberg R.L., Moawad A.H. et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am. J. Obstet. Gynecol. 1999; 181: 1216-1221.
22. Mercer B.M., Merlino A.A. Magnesium sulfate for preterm labor and preterm birth. Obstet. Gynecol. 2009; 114 (3): 650-668.
23. Ogoma Y., Kobayashi H., Fujii T., Kondo Y., Hachimori A., Shimizu T., Hatano M. Binding study of metal ions to S100 protein: 43Ca, 25Mg, 67Zn and 39K n.m.r. Int. J. Biol. Macromol. 1992; 14 (5): 279-286.
24. Qina J., Chaia G., Brewerb J.M., Lovelacea L.L., Lebiodaa L. Structures of asymmetric complexes of human neuron specific enolase with resolved substrate and product and an analogous complex with two inhibitors indicate subunits interaction and inhibitors cooperativity. J. Inorg. Biochem. 2012 June; 111: 187-194.
25. Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am. J. Ther. 2001; 8 (5): 345-357.
26. Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16 000 individuals. Magnes Res. 2001; 14 (4): 283-90.28, 30.
27. Rouse D.J., Hirtz D.G., Thom E., Varner M.W. et al. Eunice Kennedy Shriver NICHD Maternal- Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 2008; 359 (9): 895-905.
28. Schimatschek H.F., Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 2001 Dec; 14 (4): 283-90.
29. Schreier B., Hocker B. Engineering the enolase magnesium II binding site: implications for its evolution. Biochemistry. 2010; 49: 7582-7589.
30. Spätling L., Disch G., Classen H.G. Magnesium in pregnant women and the newborn. Magnes Res. 1989 Dec; 2 (4): 271-80.
31. Sriboonlue P., Jaipakdee S., Jirakulsomchok D., Mairiang E., Tosukhowong P., Prasongwatana V., Savok S. Changes in erythrocyte contents of potassium, sodium and magnesium and Na, K-pump activity after the administration of potassium and magnesium salts. J. Med. Assoc. Thai. 2004; 87 (12): 1506-1512.
32. WHO – recommended definitions, terminology and format for statistical tables related to perinatal period and use of a new certificate for cause of perinatal deaths. Acta Obstet. Gynecol. Scand. 1977; 56 (3): 247–253.WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. World Health Organization, Dept. of Reproductive Health and Research, Dept. of Maternal, Newborn, Child and Adolescent Health, Dept. of Nutrition for Health and Development. 2011. 38 p.
33. Wynn A., Wynn M. Magnesium and other nutrient deficiencies as possible causes of hypertension and low birthweight. Nutr. Health. 1988; 6 (2): 69-88.
34.
35.
Review
For citations:
Dadak K., Makatsariya A.D., Blinov D.V., Zimovina U.V. CLINICAL AND BIOCHEMICAL ASPECTS OF THE USE OF MAGNESIUM IN OBSTETRICS, GYNECOLOGY AND PERINATOLOGY. Obstetrics, Gynecology and Reproduction. 2014;8(2):69-78. (In Russ.)
Views:
796
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
